Scarica l'app Stockscreener
97.60
2.43%
-2.43
Precedente Chiudi:
$100.03
Aprire:
$99.43
Volume 24 ore:
842.64K
Relative Volume:
0.92
Capitalizzazione di mercato:
$5.34B
Reddito:
$1.34M
Utile/perdita netta:
$-173.66M
Rapporto P/E:
-23.58
EPS:
-4.1385
Flusso di cassa netto:
$-130.49M
1 W Prestazione:
+3.46%
1M Prestazione:
+27.72%
6M Prestazione:
+155.56%
1 anno Prestazione:
+373.56%
Intervallo 1D:
$94.65
$100.84
Intervallo di 1 settimana:
$90.52
$102.33
Portata 52W:
$18.08
$102.33
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
97.60 | 5.34B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com Nigeria
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Canada
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Dianthus Therapeutics (DNTH) Starts Phase 3 Trial, Is The Stock Still A Bargain? - Sahm
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Dianthus Therapeutics stock hits 52-week high at 96.85 USD - Investing.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Dianthus launches phase 3 trial for myasthenia gravis treatment By Investing.com - Investing.com UK
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis - The Manila Times
Dianthus launches Phase 3 study of claseprubart in rare muscle disease - Stock Titan
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell Microcap Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to earnings forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Price to sales forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Enterprise value to EBIT forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Dianthus Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionCost Structure Review - dars.gov.et
Price to book forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
DNTH Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E) - TradingView
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
A3ERZ4 Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics Inc (DNTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why is Dianthus Therapeutics stock trading higher on Friday? - MSN
DNTH Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics Inc (DNTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - The Globe and Mail
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Dianthus Therapeutics Inc (DNTH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dianthus Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | 87E | US2528281080 - marketscreener.com
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):